Neoadjuvant Nivolumab for Operable Esophageal Carcinoma
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
This is a single arm phase II study, in which maximum 3 cycles of nivolumab (240 mg fixed
dose every 2 weeks) is administered for T2- or T3-node negative esophageal squamous cell
carcinoma, before curative operation.